Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.60 |
| ▸ | CCR2 | P41597 | 2/20 | 0.60 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.59 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CCR5 | P51681 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050790 | 0.92 | PTPN1 (0.61) | CCR1CCR2CACNA1HCACNA1BCCR5 | |
| SCHEMBL3148243 | 0.91 | CCR2 (0.70) | CCR1CCR2CCR5 | |
| SCHEMBL3054749 | 0.91 | CCR1 (0.54) | CCR1CCR2PTGDR2CACNA1HCACNA1B | |
| SCHEMBL4043636 | 0.89 | PTGDR2 (0.57) | CCR1CCR2PTGDR2CACNA1HCACNA1B | |
| SCHEMBL3274401 | 0.89 | POLB (0.72) | CCR1CCR2PTGDR2CACNA1HCACNA1B | |
| SCHEMBL3048026 | 0.88 | CCR1 (0.51) | CCR1CCR2PTGDR2CACNA1HCACNA1B | |
| SCHEMBL3050536 | 0.88 | CACNA1H (0.62) | CCR1CCR2CACNA1HCACNA1BCCR5 | |
| SCHEMBL3050565 | 0.87 | CCR2 (0.64) | CCR1CCR2PTGDR2CCR5PTPN1 | |
| SCHEMBL3144199 | 0.85 | CCR2 (0.68) | CCR1CCR2PTGDR2CCR5CYP1A2 | |
| SCHEMBL8711266 | 0.84 | POLB (0.78) | POLBL3MBTL1SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | disclosed |
| US-8481527-B2 | Benzamide derivatives as bradykinin antagonists | RICHTER GEDEON NYRT. (HU) | 2013-07-09 | — | — | US | disclosed |
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2012-11-22 | — | — | US | disclosed |
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-11-25 | — | — | US | disclosed |
| EP-2215055-A1 | NEW NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | Richter Gedeon Nyrt. (HU) | 2010-08-11 | — | — | EP | disclosed |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-29 | — | — | US | disclosed |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-08 | — | — | US | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
| EP-2076491-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-08 | — | — | EP | disclosed |
| EP-2074083-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-01 | — | — | EP | disclosed |
| EP-2057116-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009053763-A1 | NEW NON-PEPTIDE DERIVATIVES AS BRADYKININ BL ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008068540-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008050167-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050168-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | CCR1 333/4885CCR2 390/4885PTGDR2 225/4885 |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | CCR1 358/4885CCR2 417/4885PTGDR2 83/4885 |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | CCR1 369/4885CCR2 371/4885PTGDR2 233/4885 |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | CCR1 302/4885CCR2 359/4885PTGDR2 244/4885 |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | CCR1 302/4885CCR2 380/4885PTGDR2 195/4885 |
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, NPBWR1 | CCR1 239/4885CCR2 611/4885PTGDR2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.